These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 15671559)

  • 41. No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin.
    Mesquita B; Veiga I; Pereira D; Tavares A; Pinto IM; Pinto C; Teixeira MR; Castedo S
    BMC Cancer; 2005 Aug; 5():101. PubMed ID: 16095531
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability.
    Poruchynsky MS; Kim JH; Nogales E; Annable T; Loganzo F; Greenberger LM; Sackett DL; Fojo T
    Biochemistry; 2004 Nov; 43(44):13944-54. PubMed ID: 15518543
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The selection of taxol resistance associated genes in ovarian cancer cell line by mRNA DD].
    Cheng G; Tian F; Li Y
    Zhonghua Yi Xue Za Zhi; 2000 Jul; 80(7):541-3. PubMed ID: 11798816
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel.
    Roque DM; Buza N; Glasgow M; Bellone S; Bortolomai I; Gasparrini S; Cocco E; Ratner E; Silasi DA; Azodi M; Rutherford TJ; Schwartz PE; Santin AD
    Clin Exp Metastasis; 2014 Jan; 31(1):101-10. PubMed ID: 24005572
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Expression of class III beta tubulin in cervical cancer patients administered preoperative radiochemotherapy: correlation with response to treatment and clinical outcome.
    Ferrandina G; Martinelli E; Zannoni GF; Distefano M; Paglia A; Ferlini C; Scambia G
    Gynecol Oncol; 2007 Feb; 104(2):326-30. PubMed ID: 17030352
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.
    Okamoto A; Nikaido T; Ochiai K; Takakura S; Saito M; Aoki Y; Ishii N; Yanaihara N; Yamada K; Takikawa O; Kawaguchi R; Isonishi S; Tanaka T; Urashima M
    Clin Cancer Res; 2005 Aug; 11(16):6030-9. PubMed ID: 16115948
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study.
    ; Secord AA; Lee PS; Darcy KM; Havrilesky LJ; Grace LA; Marks JR; Berchuck A
    Gynecol Oncol; 2006 Jun; 101(3):390-7. PubMed ID: 16551475
    [TBL] [Abstract][Full Text] [Related]  

  • 48. beta-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells.
    Gökmen-Polar Y; Escuin D; Walls CD; Soule SE; Wang Y; Sanders KL; Lavallee TM; Wang M; Guenther BD; Giannakakou P; Sledge GW
    Cancer Res; 2005 Oct; 65(20):9406-14. PubMed ID: 16230404
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of polymorphisms at beta tubulin isotype 1 codons 167 and 200 in benzimidazole resistance in cyathostomins.
    Hodgkinson JE; Clark HJ; Kaplan RM; Lake SL; Matthews JB
    Int J Parasitol; 2008 Aug; 38(10):1149-60. PubMed ID: 18367189
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
    Gorovetz M; Baekelandt M; Berner A; Trope' CG; Davidson B; Reich R
    Gynecol Oncol; 2006 Dec; 103(3):831-40. PubMed ID: 16919315
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins.
    Tommasi S; Mangia A; Lacalamita R; Bellizzi A; Fedele V; Chiriatti A; Thomssen C; Kendzierski N; Latorre A; Lorusso V; Schittulli F; Zito F; Kavallaris M; Paradiso A
    Int J Cancer; 2007 May; 120(10):2078-85. PubMed ID: 17285590
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines.
    Takeda M; Mizokami A; Mamiya K; Li YQ; Zhang J; Keller ET; Namiki M
    Prostate; 2007 Jun; 67(9):955-67. PubMed ID: 17440963
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia.
    Verrills NM; Po'uha ST; Liu ML; Liaw TY; Larsen MR; Ivery MT; Marshall GM; Gunning PW; Kavallaris M
    J Natl Cancer Inst; 2006 Oct; 98(19):1363-74. PubMed ID: 17018783
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression.
    Motamed-Khorasani A; Jurisica I; Letarte M; Shaw PA; Parkes RK; Zhang X; Evangelou A; Rosen B; Murphy KJ; Brown TJ
    Oncogene; 2007 Jan; 26(2):198-214. PubMed ID: 16832351
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tubulin-targeted drug action: functional significance of class ii and class IVb beta-tubulin in vinca alkaloid sensitivity.
    Gan PP; Kavallaris M
    Cancer Res; 2008 Dec; 68(23):9817-24. PubMed ID: 19047161
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular mechanisms of patupilone resistance.
    Mozzetti S; Iantomasi R; De Maria I; Prislei S; Mariani M; Camperchioli A; Bartollino S; Gallo D; Scambia G; Ferlini C
    Cancer Res; 2008 Dec; 68(24):10197-204. PubMed ID: 19074887
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mutations at leucine 215 of beta-tubulin affect paclitaxel sensitivity by two distinct mechanisms.
    Wang Y; Yin S; Blade K; Cooper G; Menick DR; Cabral F
    Biochemistry; 2006 Jan; 45(1):185-94. PubMed ID: 16388594
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors.
    L'Espérance S; Popa I; Bachvarova M; Plante M; Patten N; Wu L; Têtu B; Bachvarov D
    Int J Oncol; 2006 Jul; 29(1):5-24. PubMed ID: 16773180
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prediction of response to docetaxel by quantitative analysis of class I and III beta-tubulin isotype mRNA expression in human breast cancers.
    Hasegawa S; Miyoshi Y; Egawa C; Ishitobi M; Taguchi T; Tamaki Y; Monden M; Noguchi S
    Clin Cancer Res; 2003 Aug; 9(8):2992-7. PubMed ID: 12912947
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Expression of COP9, JAK2, HSP and NADH in ovarian carcinoma tissues after taxol-chemotherapy and their significance].
    Li HX
    Zhonghua Fu Chan Ke Za Zhi; 2008 Jul; 43(7):528-32. PubMed ID: 19080518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.